Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review

Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by $1.13

March 2, 2021 6:52 AM EST

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.96, $1.13 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $53.16 million.

2021 Expense Guidance:

R&D spend in 2021, on a non-GAAP basis, is... More